DCTH Alerted by TOONICESTOCKS @ $6.77 hit Intraday high of $7.75 today - 4/4 on MultidayPicks now and HUGE NEW PICK COMING SOON!
I have a Monster Pick coming very soon, stay tune! Only winners, with DCTH up, we are 4/4 in Multi-day Runners. We will be announcing a big pick hopefully by this week!
Below is the message sent to Premier VIPs last Thursday on 3/26/10.
In the meantime keep an eye on Delcath Systems, Inc. (Public, NASDAQ:DCTH), ever since the beginning of this year it has been on a bullish outbreak, look at the chart from January 2010. If you have some money longer term money you might want to pick up for a quick profit, this is a pricer stock of course, currently at $6.77. They plan to release their pivotal phase III data "The next operational milestone for our company is the April completion of data analysis from our Phase III trial," said Mr. Hobbs. "The trial's data analysis involves the initial review by the principal clinical investigators at each enrolling center, an additional review by the Company's retained Clinical Research Organization, and a final review of medical images for verification of results conducted by an independent core lab before final statistical results are compiled by an independent biostatistical group. We remain highly confident that the trial's data will meet the trial's primary endpoint, and our confidence was recently further buoyed by the FDA's acknowledgement of an expanded access program,"
OR YOU CAN WAIT TO SEE WHAT THE NEWS WILL BE AND PLAY THE BOUNCE LIKE WE DID WITH CTIC. Shares will continue to run up until the data is released, however I rather not gamble and just play DCTH for a week or two for some profit.
I found this from a recent article:
Delcath Systems (Nasdaq: DCTH) is a $246.4 million New York-based drug developer focused on treatments for liver cancer. The company expects data from its current clinical trial available in the next month and to submit its FDA application for its first approval, a treatment for metastatic melanoma of the liver -- skin cancer that has spread to the liver -- by the middle of this year.
The treatment isolates the liver from the rest of the body by restricting blood flow. Then, a huge dose of chemotherapy, about ten times what is typically administered intravenously, is given to the liver. But since it is targeted and not spread throughout the body, the liver sees about 100 times more drugs. Blood in the liver is then removed, cleaned of the toxic drugs, and returned to the body. This delivery system allows for much more of the drugs to go where doctors want them while minimizing the amount of drugs that get exposed to the rest of the body.
While focused on the liver, the company's drug delivery technique could be more broadly used. Other organs can be isolated and treated in the same manner, and the company plans to address these in the future, either itself or through partnership deals. The company has received the go-ahead from the FDA to begin Phase III trials for its treatment on primary liver cancer, but it is currently looking for partners in Asia to do the study as it will be less expensive and easier to find patients. In February, Delcath announced an agreement with the Taiwanese company Chi-Fu Trading. The agreement gives Chi-Fu the exclusive right to market Delcath's liver treatment in Taiwan and could bring in up to $10 million for the company, assuming the treatment received the necessary approvals.
As a biotech development company, Delcath has no revenue. If the company gets its drug approved, an investment would likely pay off big time. In the meantime, good news in the coming month could move shares upward.
The company has said that it expects approval of its treatment for metastatic melanoma of the liver in mid-2011. At the end of 2009, the company had about $35.5 million in cash, no debt, and a burn-rate of about $1.8 million per month.
Risk-tolerant investors looking for big potential upside may consider DCTH. Keep in mind, however, that bad news from its clinical trials or from the FDA could push shares down quickly.